Your patient deserves the best. Choose CanAssist Breast - the only prognostic test validated in Indian and Caucasian patients

What Makes CanAssist Breast Unique?

Key Highlights of CAB

- Validated in India, US, Spain, Germany, Austria,The Netherlands, Turkey
- Used by patients across India, Middle East
- Concordance of **83%** with ODX and Mammaprint
- Included in *AGOS, ISMPO, ABSI guidelines.
- 5 year prospective Real world use of CAB shows accuracy of **98%**

*Asian Geriatric Oncology Society,
Indian Society of Medical & Paediatric Oncology,
Association of Breast Surgeons of India

Know the risk of breast cancer recurrence and personalise the treatment through CanAssist Breast

CanAssist Breast (CAB) is the **first AI-driven immunohistochemistry based prognostic test,** providing crucial insights into breast cancer recurrence risk.

By analyzing key tumor biomarkers, CAB helps oncologists assess whether a patient is at **"low-risk"** or **"high-risk"** for recurrence, guiding treatment decisions, including the need for chemotherapy.

5 year prospective Real world use of CAB shows accuracy of 98%

CanAssist Breast Trusted World Wide

Globally validated across three continents in India, USA, Spain, Germany, Italy, Austria, The Netherlands & Turkey

■ *Validated*

Global Reach of CanAssist Breast Since 2016

- INDIA
- TURKEY
- UAE
- SAUDI ARABIA
- SRI LANKA
- BANGLADESH
- IRAN

From India for the world
1st prognostic test made in India

Patient Testimonials

Today, I am symptom-free for over five years, and I have reclaimed my kitchen, experimenting, and enhancing my culinary skills.

Safinaz Begum
Breast Cancer Survivor

+91 96866 96505
www.oncostem.com

Thanks to CanAsisst breast, many patients can learn about their risks in early-stage breast cancer in a more economical way. With CanAssist breast, we can reach more patients. We can prevent many patients from receiving unnecessary Chemotherapy.

Dr. Esin Oktay
Associate Professor - Medical Oncologist
from Aydin Adnan Menderes University Medical School
Medical Oncology Dept., TURKEY

www.oncostem.com

Year 2017 was a year which will never fade away as I was victorious in defeating breast cancer, but the battle was too hard. Armed with knowledge from my previous experience, in 2021 when I was re-diagnosed with breast cancer I took CanAssist Breast (CAB) - a prognostic test by OncoStem. CAB indicated this tumour was not very aggressive and I have a low risk for breast cancer recurrence hence I avoided chemotherapy. CanAssist Breast - the prognostic test empowered me to defeat cancer the second time with ease and OncoStem helped in closing the gap in cancer treatment.

- **Rita Singal**, Breast cancer fighter

World Cancer Day 4 February | Close the care gap | UICC

I am Reena, an auto driver's wife. I was diagnosed with breast cancer and underwent surgery. The only information I had was, the surgery will be followed by painful treatment called chemotherapy. I was scared. But things changed after I opted for CanAssist Breast (CAB) - a prognostic test by OncoStem. Chemotherapy was not in my list. I am grateful to my oncologist who suggested CAB and to OncoStem in bridging the gap in cancer treatment.

- **Reena**, Breast cancer fighter

World Cancer Day 4 February | Close the care gap | UICC

Avoided chemotherapy the second time- because of CAB!

Thankful for an economical test!

Published In (Latest Publications)

Clinical Breast Cancer
(August 2025)

Scientific Reports
(August 2025)

Therapeutic Advances
(May 2025)

Presented At

ESMO BREAST CANCER

ESMO

SAN ANTONIO BREAST CANCER SYMPOSIUM

ASCO
American Society of Clinical Oncology

BREASTANBUL
THE CONFERENCE

Asia-Pacific Breast Cancer Summit

Accredited By

UL REGISTERED FIRM

CAP ACCREDITED
COLLEGE of AMERICAN PATHOLOGISTS

Website

oncostem.com

M: +91 96866 96505
T: +91 80 222 400 34
E: info@oncostemdiagnostics.com
W: www.oncostem.com

OncoStem Diagnostics Pvt. Ltd.
#4, Raja Ram Mohan Roy Road,
Aanand Tower, 2nd Floor, Bangalore - 560027